Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae542 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Jordan A Burdeau und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Fluorocarbons, Adiposity, Alkanesulfonic Acids, Prenatal Exposure Delayed Effects. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, National Institutes of Health's National Research Service Award, NIH HHS.
Abstract (Originalsprache)
Context
Evidence suggests that exposure to per- and polyfluoroalkyl substances (PFAS) increases the risk of developing cardiometabolic disease risk factors. Limited research has evaluated associations between PFAS, assessed during pregnancy, a sensitive window for maternal endocrine effects, and long-term maternal adiposity.
Objective
Estimate associations of early pregnancy measures of individual PFAS, and PFAS mixtures, with maternal adiposity in midlife.
Methods
We studied 547 Project Viva participants with measures of early pregnancy (mean gestation 10.0 weeks; mean age 32.5 years) plasma concentrations of 6 PFAS and midlife adiposity outcomes (mean follow-up 17.7 years; mean age 50.7 years), including weight, waist circumference (WC), trunk fat mass (TFM), and total body fat mass (TBFM). We used linear regression and Bayesian Kernel Machine Regression (BKMR).
Results
Linear regression estimated higher midlife weight per doubling of perfluorooctane sulfonate (PFOS) (3.8 kg [95% CI: 1.6, 5.9]) and 2-(N-ethyl-perfluorooctane sulfonamido) acetate (2.3 kg [95% CI: 0.9, 3.7]). BKMR analyses of single PFAS plasma concentrations (comparing the 25th percentile concentration to the 75th percentile) showed a positive association between PFOS and midlife adiposity (weight: 7.7 kg [95% CI: 4.0, 11.5]; TFM: 1.2 kg [95% CI: 0.0, 2.3]; TBFM: 3.0 kg [95% CI: 0.8, 5.2]), but inverse associations with perfluorononanoate (weight: −6.0 kg [95% CI: −8.5, −3.5]; WC: −1.8 cm [95% CI: −3.2, −0.3]; TFM: −0.8 kg [95% CI: −1.5, −0.1]; TBFM: −1.4 kg [95% CI: −2.7, −0.3]) and perfluorohexane sulfonate (TFM: −0.8 kg [95% CI: −1.5, −0.1]; TBFM: −1.4 kg [95% CI: −2.6, −0.2]). No associations were observed with the overall PFAS mixture.
Conclusion
Select PFAS, assessed in pregnancy, may differentially affect maternal midlife adiposity, influencing later-life maternal cardiometabolic health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
- Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Division of Chronic Disease Research Across the Lifecourse, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA 02215, USA.
ORCID-Profile: Jordan A Burdeau, Briana J K Stephenson, Antonia M Calafat, Tamarra James-Todd
Förderung
- NIEHS NIH HHS
- National Institutes of Health's National Research Service Award
- NIH HHS
- NICHD NIH HHS
- National Institutes of Health’s National Research Service Award
- National Institutes of Health
Zitieren
APA
Burdeau, J. A., Stephenson, B. J. K., Chavarro, J. E., Mahalingaiah, S., Preston, E. V., Hivert, M. F., Oken, E., Calafat, A. M., Rifas-Shiman, S. L., Zota, A. R., & James-Todd, T. (2025). Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae542
Vancouver
Burdeau JA, Stephenson BJK, Chavarro JE, Mahalingaiah S, Preston EV, Hivert MF, et al. Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae542
BibTeX
@article{Burdeau2025,
author = {Burdeau, Jordan A and Stephenson, Briana J K and Chavarro, Jorge E and Mahalingaiah, Shruthi and Preston, Emma V and Hivert, Marie-France and Oken, Emily and Calafat, Antonia M and Rifas-Shiman, Sheryl L and Zota, Ami R and James-Todd, Tamarra},
title = {Early Pregnancy Plasma Per- and Polyfluoroalkyl Substances (PFAS) and Maternal Midlife Adiposity},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae542}
}
EUVIMED